At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
tissue plasminogen activator +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Thrombolysis in Myocardial Infarction (TIMI)
National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Mar 16, 2016
In Brief
A Phase 3 clinical trial evaluating tissue plasminogen activator and angioplasty, transluminal, percutaneous coronary for Cardiovascular Diseases and 4 related conditions. Completed.
Detailed Summary
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Infarction, Myocardial Ischemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 1983
Study CompletionDec 1990
First PostedOct 1999
TodayJul 2026
First PostedOct 28, 1999
Enrollment StartApr 1, 1983
Study CompletionDec 1, 1990
TodayJul 2, 2026
Posted 26.7 years ago
Interventions
tissue plasminogen activatordrug
angioplasty, transluminal, percutaneous coronaryprocedure